Alvotech's AVT06 Biosimilar Gains Marketing Application Acceptance from EMA

Introduction

Alvotech, a leading biotechnology company, has received the European Medicines Agency's (EMA) acceptance of its marketing application for AVT06, a biosimilar to Humira.

This acceptance marks a significant milestone for Alvotech and represents a step forward in providing patients with access to high-quality, affordable biosimilar medicines.

EMA Approval Timeline

• Marketing application accepted: August 15, 2024
• Approval process expected to be completed: Q3 2025